Deallus white papers

The latest white papers from Deallus pharmaceutical and life science industry experts

HIV/AIDS

2022-12-01T11:26:10+00:00News, White Paper|

Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).

Deallus Workshops: providing competitive advantage through Competitive Simulation

2022-11-24T09:54:46+00:00White Paper|

Competitive Simulation, also known as Competitive Strategy or ‘Wargaming’ workshops, account for roughly 85% of the workshops that Deallus run. We have developed a detailed and comprehensive workshop playbook that ensures our teams are well-prepared and well-versed with a set of tools ready to run your sessions.

The future for telehealth and neuroscience in the US

2022-06-01T14:30:15+01:00Thought Piece, White Paper|

Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.

Disruption has hit pharma

2022-09-29T17:19:28+01:00White Paper|

Strategic intelligence for a fiercely competitive marketplace. In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. Deallus look at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.

Go to Top